Epidiolex
DrugAdministered as an oral solution
Other names: Cannabidiol, Epidyolex
NCT Number: NCT05772429
This is a multi-center, non-interventional and prospective study of patients receiving Epidyolex as part of standard clinical practice in France. The study will state an overview of patient characteristics and clinical history (including age, sex, diagnosis, duration of epilepsy, predominant seizure type, previous medications, current co-medications and Epidyolex dose), and an evaluation of retention rates, safety profile, seizure activity, changes in executive function and quality of life measured in a 2-year follow-up period.
This study is active but is not currently recruiting participants.
Notify Me2 year and older
All sexes
Observational
CHU Amiens-service adulte, Amiens, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Administered as an oral solution
Other names: Cannabidiol, Epidyolex
Time frame: Up to 24 months post-dose.
Retention rate will be measured through assessing the frequency of seizures and the length of time on treatment before a seizure event.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Baseline; Up to 24 months post-dose.
The BRIEF-P is a 63-item questionnaire which consists of a single Rating Form used by parents, teachers, and day care providers to assess a child's executive functions within the context of their everyday environments--home and preschool. High scores obtained on the BRIEF-P suggest a higher level of dysfunction in a specific domain of executive functions. The BRIEF rating scores is an ordinal set of a technically summarized degree of disorder in functionality: Never = 1 (Minimum), Sometimes = 2 and Often = 3 (Maximum).
Time frame: Baseline; Up to 24 months post-dose.
BRIEF is an 86-item questionnaire used to assess the executive function behaviors at home and at school for children and adolescents ages 5-18. High scores obtained on the BRIEF suggest a higher level of dysfunction in a specific domain of executive functions. The BRIEF rating scores is an ordinal set of a technically summarized degree of disorder in functionality: Never = 1 (Minimum), Sometimes = 2 and Often = 3 (Maximum).
Time frame: Baseline; Up to 24 months post-dose.
BRIEF-A is a patient-reported scale to measure various aspects of adult executive functioning and self-regulation in the person's everyday environment. It is a 75-item questionnaire that participants rate on a 3-point Likert scale (1 = behavior is never observed to 3 = behavior is often observed). Higher scores indicate greater impairment in executive functioning.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
Time frame: Up to 24 months post-dose.
A month is defined as 28 days.
Time frame: Up to 24 months post-dose.
The PGIC comprises the following question: "Please assess the change in the patient's general functional abilities since enrollment," scored on a seven-point scale from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores on the scale indicate a better quality of life.
Time frame: Up to 24 months post-dose.
The CGIC comprises of the following question: "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)," scored on a seven-point scale from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores on the scale indicate a better quality of life.
Time frame: Up to 24 months post-dose.
The HUI-2 is a generic measure of health status and health-related quality of life. There are 15 questions in the questionnaire with 1-week recall completed by the caregiver. Answers to the questionnaire are mapped into a classification system of 7 sets of utility scores (sensation, mobility, emotion, cognition, self-care, pain, and fertility) with a scoring scale of a minimum score of 0.00 (lack of functional capacity or most disabled) to a maximum of 1.00 (full function or no disability). A higher score indicates a better outcome.
Jazz Pharmaceuticals
Industry
Long-term Follow-up of a Multicentre, Non-interventional, Prospective Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
Acronym: OPERA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07125261
Brain Diseases, Central Nervous System Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT06922734
Brain Diseases, CT Scan
Maribor, Slovenia
View Trial DetailsNCT05339126
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02813980
Brain Diseases, Cardiovascular Diseases
Rochester, Minnesota, United States
View Trial Details